Physician profile
Michelle Cummins
NPI 1104433226
$2,232.77
in general payments reported to CMS, 2019-2025
14 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,063 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $687.37 | 2024-2025 | Augment Injectable, Ortholoc 2 Lapifuse, N/A |
| Treace Medical Concepts, INC. | $221.76 | 2024-2025 | |
| Exactech, INC. | $212.75 | 2024 | |
| Alafair Biosciences, INC. | $204.93 | 2024-2025 | Versawrap |
| Depuy Synthes Sales INC. | $178.76 | 2025 | Motoband, Hammerlock |
| Smith+Nephew, INC. | $174.93 | 2025 | Collagenase Santyl, Stravix, Grafix |
| Avita Medical Americas, LLC | $134.60 | 2025 | Recell |
| Curonix LLC | $110.70 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Paragon 28, INC. | $99.72 | 2024 | Bun-Yo-Matic |
| Paratek Pharmaceuticals, INC. | $61.34 | 2025 | Nuzyra |
| Amgen INC. | $49.37 | 2024-2025 | Krystexxa |
| Orthofix Medical, INC. | $46.01 | 2025 | Physio-Stim |
| Ani Pharmaceuticals, INC. | $26.68 | 2025 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $23.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cummins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.